164 related articles for article (PubMed ID: 22381714)
1. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens RC
Clin Ther; 2012 Mar; 34(3):654-67. PubMed ID: 22381714
[TBL] [Abstract][Full Text] [Related]
2. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.
Tong G; Castaneda L; Wang JS; Sverdlov O; Huang SP; Slemmon R; Gu H; Wong O; Li H; Berman RM; Smith C; Albright C; Dockens RC
Clin Drug Investig; 2012 Nov; 32(11):761-9. PubMed ID: 23018285
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Dockens R; Wang JS; Castaneda L; Sverdlov O; Huang SP; Slemmon R; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Tong G
Clin Pharmacokinet; 2012 Oct; 51(10):681-93. PubMed ID: 23018531
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Albright CF; Dockens RC; Meredith JE; Olson RE; Slemmon R; Lentz KA; Wang JS; Denton RR; Pilcher G; Rhyne PW; Raybon JJ; Barten DM; Burton C; Toyn JH; Sankaranarayanan S; Polson C; Guss V; White R; Simutis F; Sanderson T; Gillman KW; Starrett JE; Bronson J; Sverdlov O; Huang SP; Castaneda L; Feldman H; Coric V; Zaczek R; Macor JE; Houston J; Berman RM; Tong G
J Pharmacol Exp Ther; 2013 Mar; 344(3):686-95. PubMed ID: 23275065
[TBL] [Abstract][Full Text] [Related]
5. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens R
Br J Clin Pharmacol; 2013 Jan; 75(1):136-45. PubMed ID: 22616739
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
7. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
Coric V; Salloway S; van Dyck CH; Dubois B; Andreasen N; Brody M; Curtis C; Soininen H; Thein S; Shiovitz T; Pilcher G; Ferris S; Colby S; Kerselaers W; Dockens R; Soares H; Kaplita S; Luo F; Pachai C; Bracoud L; Mintun M; Grill JD; Marek K; Seibyl J; Cedarbaum JM; Albright C; Feldman HH; Berman RM
JAMA Neurol; 2015 Nov; 72(11):1324-33. PubMed ID: 26414022
[TBL] [Abstract][Full Text] [Related]
8. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat.
Simutis FJ; Sanderson TP; Pilcher GD; Graziano MJ
Toxicol Sci; 2018 Jun; 163(2):525-542. PubMed ID: 29529279
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
11. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
14. The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers.
Soares HD; Gasior M; Toyn JH; Wang JS; Hong Q; Berisha F; Furlong MT; Raybon J; Lentz KA; Sweeney F; Zheng N; Akinsanya B; Berman RM; Thompson LA; Olson RE; Morrison J; Drexler DM; Macor JE; Albright CF; Ahlijanian MK; AbuTarif M
J Pharmacol Exp Ther; 2016 Jul; 358(1):138-50. PubMed ID: 27189973
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.
Quartino A; Huledal G; Sparve E; Lüttgen M; Bueters T; Karlsson P; Olsson T; Paraskos J; Maltby J; Claeson-Bohnstedt K; Lee CM; Alexander R; Fälting J; Paulsson B
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):396-405. PubMed ID: 27129013
[TBL] [Abstract][Full Text] [Related]
16. BMS-708,163 targets presenilin and lacks notch-sparing activity.
Crump CJ; Castro SV; Wang F; Pozdnyakov N; Ballard TE; Sisodia SS; Bales KR; Johnson DS; Li YM
Biochemistry; 2012 Sep; 51(37):7209-11. PubMed ID: 22931393
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h.
Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I
Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects.
Qiu R; Ahn JE; Alexander R; Brodney MA; He P; Leurent C; Mancuso J; Margolin RA; Tankisheva E; Chen D
J Alzheimers Dis; 2019; 71(2):581-595. PubMed ID: 31424395
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
20. Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.
Probst G; Aubele DL; Bowers S; Dressen D; Garofalo AW; Hom RK; Konradi AW; Marugg JL; Mattson MN; Neitzel ML; Semko CM; Sham HL; Smith J; Sun M; Truong AP; Ye XM; Xu YZ; Dappen MS; Jagodzinski JJ; Keim PS; Peterson B; Latimer LH; Quincy D; Wu J; Goldbach E; Ness DK; Quinn KP; Sauer JM; Wong K; Zhang H; Zmolek W; Brigham EF; Kholodenko D; Hu K; Kwong GT; Lee M; Liao A; Motter RN; Sacayon P; Santiago P; Willits C; Bard F; Bova MP; Hemphill SS; Nguyen L; Ruslim L; Tanaka K; Tanaka P; Wallace W; Yednock TA; Basi GS
J Med Chem; 2013 Jul; 56(13):5261-74. PubMed ID: 23713656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
